Since raloxifene, a drug used in osteoporosis therapy, inhibits osteoclast, but not osteoblast functions, it has been suggested to improve recovery during implant surgery. The present paper describes an effective method to link raloxifene, through a covalent bond, to a nano-Hydroxyapatite-based biomaterial by interfacing with (3-aminopropyl)-Triethoxysilane as assessed by Infra Red-Fourier Transformed (lR-FT) spectroscopy and Scanning Electron Microscope (SEM). To evaluate the safety of this modified new material, the vitality of osteoblast-like ceUs cultured with the new biomaterial was then investigated. Raloxifene-conjugated HAbiomaterial has been shown to be a safe material easy to obtain which could be an interesting starting point for the use of a new functional biomaterial suitable in bone regeneration procedures.
Currently in oral surgery, research is focused on the use of biomaterials to facilitate bone repair processes (I ). Moreover, the trend in the latest research aims to match these biomaterials, mostly with osteoconductor capabilities, with molecules that have an osteoinductive effect. The use ofbiomaterials as a carrier for different types of molecules has already been tested in some investigations. Many studies have been carried out on bio glass, alone or in special preparations, such as incorporated in a foam of poly-OL-Iactic acid (POLLA) (2) . Certainly, the greatest interest is elicited by those studies in which biomaterials are associated with other molecules such as collagen-hyaluronic acid-phosphatidylserine (BG-COL-HY A-PS) (3) or with osteoinductive proteins such as recombinant bone morphogenetic protein 2 (rhBMP-2) (4). However, it should be considered that bioceramics remain embedded in bone matrix and their nature does not participate in the processes of resorption and remodeling typical ofbone physiology.
Furthermore, rhBMP-2 was tested for the ability to be carried by absorbable materials of different nature such as demineralized bone matrix (OBM), Bio-Oss"; absorbable collagen sponge (ACS); polylacticpolyglycolic acid (PLGA) micro-particles; Orilac (granules of polylactic acid), All those materials showed good results, especially Bio-Oss" and OBM (5) . Moreover, Bio-Oss" (as well as Algipore") showed a good behavior also in association with recombinant osteogenic protein 1 (rhOP 1) (6).
Other teams have tested the possibility of carrying along with hydroxyapatite (Endobon", Bio-Oss" and Algipore") TGF-pI, and even in this case, Bio-Oss® resulted the most proven to guarantee a constant release of the molecule over time (7) .
These studies urged to test the coupling of other kinds of biomaterials acting as a carrier for drugs (8) . Such attempts have already been made using biomaterials associated with bisphosphonates (9) . The effect of bisphosphonates in combination with PDLLA (10), loading of hydroxyapatite microspheres into PLGA foam (II), in combination with bioglass (12) or Bio-Oss® (13) was tested. Moreover, bisphosphonates bound to cyclodextrin and then conjugated with hydroxyapatite resulted in a complex capable of delivering also other pharmaceutical drugs such as dexamethasone with an excellent integration and a gradual and constant release of the drug (14) . Finally, the possibility of linking bisphosphonates to tantalum implant surfaces was also demonstrated (15) . However, bisphosphonates, due to their pharmacokinetic properties, revealed poor osteoinductive properties, remaining valid in maintaining bone homeostasis, thereby preventing the osteoclastic activity, but not inducing the osteoblast function.
For the above stated reason, the focus shifted on molecules that have a direct activity on bone forming cells: the selective estrogen receptor modulator (SERM) family. Studies on the possibility of combining these molecules with a carrier have already been made, for example, by incorporating the drug in silica xerogels associated with biodegradable polymers (16) . In a recent work, Bambini et al.
experimented with success the chemical modification of titanium for the covalent link with biological molecules (Raloxifene, a drug that has already been widely used systemically in postmenopausal therapy) in order to improve the integration of the implants through the selective control of the adsorbed proteins and the interactions with the interface (17) . This prompted us to investigate the possibility of bonding raloxifene to a nanohydroxyapatite biomaterial. Since this compound inhibits osteoclast functions, but not osteoblast functions, it could improve recovery during implant surgery. Therefore, the purpose of this work was to study the possibility of linking raloxifene on a biomaterial surface to be used in oral surgery.
MATERIALS AND METHODS
To avoid variations the experiment was carried out in triplicate.
Preparation ofthe biomaterial
Of 500 mg nanoHA-biomaterial (Neo Active Apatite, Ghimas, Bologna, Italy), 50 mg were used as control, while the other 450 mg were washed several times with toluene and dried under vacuum at 0.4 mmHg with a mechanical pump. After the degreasing step, the material was treated with (3-aminopropyl)-triethoxysilane (Sigma Aldrich, Italy) (\ ml) in dried toluene (10 ml) under reflux and magnetic stirring for 4 h. Then, a washing step with diethyl ether, to remove the excess of silane, was applied. 50 mg of biomaterial were kept for IR-FT and SEM analysis. The other 400 mg, following silanization, were treated with raloxifene (extracted and purified from Evista® by Eli Lilly Italia S.p.A) (20 mg) in dried toluene (4 ml), under reflux and magnetic stirring. At the end of the treatment, it was washed in diethyl ether, methanol and acetone and dried under vacuum. One half of the material was submitted to IR-FT and SEM analyses, while the other half was vapor sterilized for 30 min, prior to being submitted to IR-FT and SEM analyses.
Preparation ofpure raloxifene
Seven pellets of Evista by Lilly, containing 60 mg of Raloxifene hydrochloride, corresponding to 56 mg of free base, were powdered in a mortar. The powder obtained was treated with 5% sodium hydrogen carbonate (50 ml) and extracted with diethyl ether (100 ml). The organic solution was then separated, dried on Na ZS04 and evaporated to dryness. The residue was extracted with boiling acetone. The spontaneous evaporation of acetone gave raloxifene; 250 mg (yield 64%) m.p.140-144°C -lit. 143-147°C (12) .
FT-IR measurements
FT-IR measurements were performed on a Perkin Elmer Spectrum GX-Spectrometer equipped with a microscope. The spectra were recorded in reflectance, 16 scans, 4 em:'. Data handling were achieved with a GRAMS/32 software package by Galactic.
SEM investigation
The surface elemental analyses were performed by a scanning electron microscope Philips XL 20, equipped with a dispersive minianalyser (SEM-EDX).
Cell culture
Osteoblast-like cells (MG63) were cultured in sterile Falcon wells using Eagle's minimum essential medium (MEM) supplemented with 10% fetal calf serum (FCS) (Sigma, Chemical Co., St Louis, MO, USA). Cultures were maintained in a 5% C02 humidified atmosphere at 371C. MG63 cells were collected and seeded at a density of 1_105 cells/ml into 9cm2 (3 ml) wells. One set of wells contained the biomaterial covalently linked to Raloxifene, whereas another contained the sole biomaterial without Raloxifene covering the same area. Every 24 h, the medium (3 ml ofMEM with 10% FCS) was changed.
MTT (3-dimethylthiazol-2. 5-diphenyltetrazolium bromide) colorimetric assay
After incubation, the medium was removed; 200 lL of MTT (Sigma, Milan, Italy) solution (5 mg/mL in DMEM without phenol red) and 1.8 mL of DMEM were added to the cell monolayer; the multi-well plates were incubated at 37°C for further 4 h. After discarding the supernatants, the dark blue Formosan crystals were dissolved by adding 2 mL of solvent (10% HCl 1N in isopropanol, Sigma, Milan, Italy) and quantified spectrophotometrically (Secomam, Anthelie light, version 3.8, Contardi, Italy) at 570 and 690 nm. In the control cultures, the cells were placed directly into adherent polystyrene culture plates at the same culture density as placed onto the samples. The mean and the standard deviations were obtained from three different experiments of the same specimen.
RESULTS

Evaluation ofbiomaterial surface with IR-FT
With IR-FT technique a very broadened band, falling in the OH group region, was observed in the spectrum of the pure biomaterial. This band can be likely attributed to OH groups present on the Hydroxyapatite surface. The spectrum of silanized sample showed many bands and most of them corresponded to those observed in the IR-FT spectrum of pure (3-aminopropyl)-triethoxysilane. Furthermore, the broad band falling in the range 2750-3650cm-' and assigned to the Hydroxyapatite-OH groups, disappeared almost completely after the silanization treatment, demonstrating that most of the Hydroxyapatite-OH groups were transformed into an oxygen bridge between the Hydroxyapatite surface and the silicon atom (Fig. IA) . The idea to link raloxifene to silane was based on the fact that silane contains an amino group which could easily condense with the chetone group of raloxifene, leading to a nitrogen-carbon bond.
The IR-FT spectrum ofthe treated material showed the bands typical of pure raloxifene, especially in the range between 1400 and 1750 cm' (Fig. lA) . However, the most important observation was the change in intensity of the band of the raloxifene carbonyl group at 1720 ern", which was very low after the treatment. In fact, the decrease of this band and the higher intensity of the band at 1600 crrrI due to the formation of the carbon-nitrogen bond demonstrate that raloxifene was covalently bonded to silane.
A part of the treated material with raloxifene was vapor sterilized with the aim of assessing the stability of the bond. Noticeably, the IR-FT spectra of the material before and after the sterilization were almost overlapping, indicating that the sterilization process does not alter the binding of raloxifene to the material (Fig. 1B) .
Evaluation of biomaterial surface with SEM plus EDS
All the images collected by SEM from the various samples differ from each other, in agreement with the treatment carried out on the studied samples. Indeed, the result of this investigation showed a change in the material surface morphology. It was able to appreciate a progressive reduction in the surface porosity from the HA sample toward the raloxifene sample ( Fig. 2 A, B , C and D); indicating that the bonding process took place with the silane before and with the raloxifene after.
According to the elemental analysis performed on the sample surfaces, the simple HA sample showed the presence of calcium (Ca) and phosphorus (P); in the silanized samples it was possible to detect also the silicon (Si). In the sample containing raloxifene, not only calcium, phosphorus and silicon were present, but also sulfur (S).
Cell viability MTT test
The analysis performed on the cell viability after 72 h of contact with silanized biomaterial treated with raloxifene showed no significant differences in the growth of the cell populations tested (MG63) compared to their control. Fig. 1. A) FT-IR spectra ofHA-biomaterial (HA), HA silanizated biomaterial (HA +SI), HA silanizated biomaterial treated with raloxijene (HA +SI+RLX) and pure raloxijene (raloxijene). B) FT-IR spectra ofHA silanizated biomaterial treated with raloxifene before the vapor sterilization (HA+SI+RLX) and after the vapor sterilization (HA+SI+RLX sterilized).
differentiation of mesenchymal cells in bone cells, or determine the release of growth factors important for bone regeneration, such as BMP.
Since estrogenic therapy prevents postmenopausal bone loss (18, 19) , a new class of compounds called SERMs (Selective Estrogen Receptor Modulators), to which Raloxifene belongs, was developed to avoid well-known adverse effects of estrogens, activating estrogen receptors only in desired tissues.
As Black and collaborators established raloxifene anti-osteopenic potentiality (20, 21) , several studies demonstrated that this drug was able to maintain a constant level of bone mineralization (22) , and had a protective effect on bone density similar to estrogens (23) without the suppressive effects on bone formation index (24) .
The biological effects that raloxifene exert on bone tissue encouraged us to experiment its use in treatments with bone graft materials in order to increase graft material bioactivity. However, binding organic molecules to an inorganic substrate requires that the substrate has functional groups on the surface that can form covalent bonds with the appropriate organic molecules . Since this does not always occur, spacers, that are capable of binding to the substrate and which contain groups suitable for being linked to other organic molecules, must be used. Another method would be to coat the substrate with a monolayer of gold and put on it thiol derivatives, which generally have a good affinity with gold. Unfortunately, it is a weak interaction and gold is not suitable for such biological applications. In our case the inorganic substrate was the hydroxyapatite, a substance that contains hydroxyl groups. Such groups may react with the 3-aminopropyl-triethoxy silane and subsequently it could be possible to condense the amino group ofthe silane with the chetone group of raloxifene. Thus, we investigated the possibility to link raloxifene to HA surface through a silane molecule. The IR-FT measurements demonstrate that silicon was covalently bonded to HA, in agreement with the literature reports (11) , and that raloxifene was covalently bonded to the amino silane through the carbon-nitrogen bond, in agreement with the well known reactivity of the amino with the carbonyl chetone group (20) . Moreover, SEM analysis displayed how the surface porosity seen in the HA sample was progressively reduced by each treatment (silanization before and addition of raloxifene after). Thus, SEM data confirmed those of IR-FT, indicating that the bonding process took place both with silane and raloxifene and that the reduction in surface porosity was due to silane and raloxifene adjunct. These results suggested that the tested treatment could effectively enhance the drug molecule adsorption, providing a homogeneous distribution in the scaffold. High capacity ofmolecule adsorption is an important property of a biomaterial! scaffold application. Researches demonstrated that cell adhesion and survival could be modulated by molecule pre-adsorption on the scaffold (25) (26) (27) . The more the molecules are adsorbed in a scaffold, the more cells can attach and survive during the initial culture period (28) (29) (30) (31) (32) .
This property was particularly desirable when facing with coupling a nano-hydroxyapatite biomaterial with a growth factor. Indeed, some studies investigated the possibility to load biomaterials with growth factor, mostly BMP-2, -7 and VEGF. Even if it seems a promising strategy to enhance bone regeneration compared to the sole biomaterial, results from these studies are difficult to compare since there is a great variability in the study design, using a coupling agent within biomaterial (i.e. Chitosan, alendronate, etc.), growth factor, and adjunct of mesenchymal stem cells (33) (34) (35) (36) .
Furthermore, according to the elemental analysis performed on the sample surfaces, the silanized samples (biomaterial+silane and biomaterial+silane+raloxifene) showed the presence of silicon, which is a certain proof of the presence of silane on the biomaterial surface. Indeed, simple HA sample showed only the presence of calcium and phosphorus and not silicon. In the sample containing raloxifene it was possible to detect also sulfur, indicating the presence of raloxifene, even if the gilding of the sample partially masks the emission of sulfur. Thus, interfacing an HA graft biomaterial with (3-aminopropyl)-Triethoxysilane constitutes a simple and effective method to link drugs or other biological molecules to biomaterial surfaces.
However, silane is not a completely safe material and it may induce noxious responses in biological systems. For the above stated reason, MG63 osteoblast-like cells were cultured with this new biomaterial to assess its effect on cell viability. Since no significant differences were observed in the growth of the cell populations tested (MG63) compared to their control after 72 h of contact with silanized biomaterial treated with raloxifene, likely the material did not show short-term toxicity. Also possible long-term noxious responses in in vivo biological systems may be elicited by silane.
However, Dupraz et al. showed that nano-HA coated with silane derivatives had good biocompatibility for use as filler in resorbable composites (37, 38). A recent work displayed that incorporating a silane coupling agent, such as 3-(trimethoxysilyl)propyl methacrylate (MPMA), into the preparation of PMMA/bioglass hybrid matrices may improve the homogenous composite formation (39), suggesting the ability of silane molecules to improve composite scaffold properties.
In conclusion, we described a simple method to link, through a covalent bond, raloxifene to HAbiomaterial by interfacing with (3-aminopropyl)triethoxysilane.
However, further studies investigating long-term silane biocompatibility and the best dose of loading material surfaces are required.
If the present results are confirmed by other studies, it is possible to suggest incorporating raloxifene in Ha biomaterial scaffolds with the aim of improving recovery during oral surgery.
